Patients with relapsed/refractory myeloma from lower socioeconomic groups face worse quality of life, even in countries with universal health care, according to Francesco Sparano, MSc, of the Italian-based GIMEMA Foundation.
Francesco Sparano, MSc
Advertisement
Francesco Sparano, MSc, is a research associate in the health outcomes research unit at the Italian-based GIMEMA Foundation.
Articles by Francesco Sparano, MSc
Patients with relapsed/refractory (R/R) multiple myeloma and lower socioeconomic status reported significantly worse quality of life and a higher burden of symptoms, according to Francesco Sparano, MSc, of the GIMEMA Foundation.
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on AJMC
1
Contributor: American Patients vs Foreign Governments—A Tale of 2 Value Sets
2
Asundexian Cuts Recurrent Stroke Risk Without More Bleeding: Mukul Sharma, MD, MSc
3
Faricimab Safe, Effective for Use in Treating nAMD in Treatment-Naive Eyes
4
Bipartisan Break Up Big Medicine Act Targets Vertical Integration in Health Care
5